GENSCRIPT BIO (01548) saw its shares rise more than 8% during the morning session. At the time of writing, the stock was up 6.84%, trading at HKD 14.68, with a turnover of HKD 107 million. The surge follows the official announcement by Eli Lilly of its acquisition of Boston-based biotechnology firm Kelonia for an upfront payment of $3.25 billion and a total potential consideration of up to $70 billion. Kelonia's core technology, iGPS, is an in vivo CAR-T platform based on a modified lentiviral vector. Guotai Haitong Securities noted that in vivo CAR-T technology offers advantages such as simplified manufacturing, improved accessibility, and strong platform extensibility, and remains optimistic about its potential as a key direction for next-generation cell therapies. Public information shows that Legend Biotech's in vivo CAR-T project, LVIVO-TaVec100 (a CD19/CD20 bispecific in vivo CAR-T generating agent), initiated a Phase I IIT clinical trial in May 2025. The bispecific targeting strategy in its design provides a more differentiated advantage and may reduce the risk of tumor immune escape due to single antigen loss.